Citius Pharmaceuticals Inc. Common

CTXRNASDAQ • USD
0.51 USD
↗ 0.01 (2.27%)AT CLOSE (03:59 PM EST)
0.51
↘ 0.00 (0.10%)
POST MARKET (AS OF 04:00 PM EST)
Post Market
AS OF 04:00 PM EST
0.51
↘ 0.00 (0.10%)
🔴Market: CLOSED

CTXR is currently priced at $0.51. Both sides of the analysis point lower: technicals flash "Strong Sell" and fundamentals confirm with a "Sell" reading. Key drivers include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, negative Return on Equity, a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. On the valuation side, CTXR appears attractively valued relative to sector peers across key multiples.

Technical & fundamental data as of Nov 20, 2026.

Open?$0.48
High?$0.51
Low?$0.48
Prev. Close?$0.50
Volume?183.7K
Avg. Volume?263.4K
VWAP?$0.49
Rel. Volume?0.70x
Bid / Ask
Bid?$0.47 × 2.0K
Ask?$0.52 × 2.0K
Spread?$0.05
Midpoint?$0.50
Valuation & Ratios
Market Cap?14.0M
Shares Out?27.5M
Float?26.0M
Float %?94.9%
P/E Ratio?N/A
P/B Ratio?0.21
EPS?-$1.69
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies.
Employees
23
Market Cap
14.0M
Industry
PHARMACEUTICAL PREPARATIONS
Listed
2011-10-18
Address
11 COMMERCE DRIVE
CRANFORD, NJ 07016
Phone: (908) 967-6676
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-2/3)
Medium-Term (Wave)?▼ Bearish(-2/3)
Short-Term (Ripple)?▼ Bearish(-2/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
0
Momentum?
65
Short Sent.?
29
Piotroski F-Score?0/9Weak
Altman Z-Score?-4.04Distress
Confidence?49%Low
Full Fundamental Analysis →
Short InterestSqueeze Risk
Short % of Float?22.14%Squeeze Risk
Short Interest?5.8M
Days to Cover?17.8
Free Float26.0M
Avg Daily Volume324.6K
Settlement Date2026-10-30
Financial Health
Current Ratio?0.84Weak
Quick Ratio?0.40Weak
Cash Ratio?0.33Low
Debt/Equity?0.10Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
100/100
P/E?
N/A▾
P/B?
Peers
100
S&P
97
0.21CHEAP▾
P/S?
Peers
100
S&P
67
1.97CHEAP▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-0.1CHEAP▾
EV/Sales?
Peers
100
S&P
97
0.48CHEAP▾
Returns & Efficiency
ROE?
S&P
3
-69.5%WEAK▾
ROA?
S&P
3
-32.5%WEAK▾
Cash Flow & Enterprise
FCF?$-34867203
Enterprise Value?$3.4M
Fundamentals ratios updated end of day